<p>2022 has not been kind to the stock market in general and the cannabis stock market in particular. U.S. cannabis stocks suffered a 20% rout in January, tumbling more than the broader market as hopes for federal marijuana legalization in the near future continued to fade.</p> <p></p> <p>Cannabis specific issues in play:</p> <p>*Retail revenue growth has slowed in several key US markets and turned negative in Canada.</p> <p>*Cannabis stocks are fighting against a rising rate induced sector rotation out of “growth” into “value.”</p> <p>*Observers have largely capitulated on hopes for federal legalization.</p> <p>*California continues to look disastrous for a large swath of competitors in 2022.</p> <p></p> <p>At least two large Canadian cannabis companies have been notified by the Nasdaq that their shares are too cheap and no longer meet the stock exchange’s listing standards.</p> <p></p> <p>During the pandemic, interest in special purpose acquisition companies (SPAC) soared, as private cannabis-related businesses looked to these blank-check companies for quicker, easier access to public markets and the funding that comes with it.</p> <p></p> <p>But two years later, the sparkle seems to be dimming.</p> <p></p> <p>Episode 887 The #TalkingHedge dives into Viridian Capital Advisors report...</p> <p>https://youtu.be/t0z7FiMlLsA</p> <p>#CannabisBanking #CannabisInvestment #WeedStocks #PotStocks #CannabisStocks #MarijuanaStocks</p>